Last reviewed · How we verify

Mecobalamin IM injection — Competitive Intelligence Brief

Mecobalamin IM injection (Mecobalamin IM injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin B12 analog. Area: Neurology; Hematology.

marketed Vitamin B12 analog Methionine synthase; B12-dependent enzymes Neurology; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Mecobalamin IM injection (Mecobalamin IM injection) — Eisai Co., Ltd.. Mecobalamin is an active form of vitamin B12 that replenishes cellular cobalamin stores and restores normal methylation and energy metabolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mecobalamin IM injection TARGET Mecobalamin IM injection Eisai Co., Ltd. marketed Vitamin B12 analog Methionine synthase; B12-dependent enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin B12 analog class)

  1. Eisai Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mecobalamin IM injection — Competitive Intelligence Brief. https://druglandscape.com/ci/mecobalamin-im-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing